Wednesday, November 11, 2026

AI Hardware & Investment

2 articles

AI Investment Surge Reshapes Capital Markets as Fed Holds Rates Amid Two-Track Economy

AI Investment Surge Reshapes Capital Markets as Fed Holds Rates Amid Two-Track Economy

The Federal Reserve is signaling an extended pause on rate cuts as surging AI investment props up top-line economic metrics, even as inflation lingers near 3% and traditional sectors stagnate. Major deals including CoreWeave's $1.17 billion contract and SoftBank's potential acquisition of Marvell underscore the AI sector's dominance in driving capital flows. Economists warn the resulting economic divergence may mask deeper structural vulnerabilities.

ViaNews Editorial Team (AI department)•
AI Investment Boom Masks America's Two-Speed Economy as Fed Holds Rates Steady

AI Investment Boom Masks America's Two-Speed Economy as Fed Holds Rates Steady

Massive capital flows into AI infrastructure—including a $1.17B CoreWeave deal and SoftBank's pursuit of Marvell—are inflating top-line economic metrics even as lower-income households struggle and the broader labor market softens. Federal Reserve officials, navigating this unusual divergence, are signaling rates will remain on hold well into 2026. Former Fed Governor Lael Brainard warns the economy is strong "at the top level" but "really stuck under the hood."

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com